AFMD
Affimed N.V.
NASDAQ · Healthcare · Biotechnology · DE
$0.18
+0.00%Income statement
| Metric | TTM | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 877.0K | 8.3M | 41.4M | 40.4M | 28.4M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | 877.0K | 8.3M | 41.4M | 40.4M | 28.4M |
| Operating Expenses | |||||
| R&D Expense | 55.9M | 95.0M | 98.8M | 81.5M | 50.0M |
| SG&A Expense | 19.0M | 24.7M | 32.1M | 24.2M | 13.7M |
| General & Admin Expense | 19.0M | 24.7M | 32.1M | 24.2M | 13.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 112.0K | (4.7M) | — | — | 626.0K |
| Total Operating Expenses | 74.6M | 114.9M | 130.9M | 105.7M | 63.7M |
| Cost and Expenses | 74.6M | 114.9M | 130.9M | 105.7M | 63.7M |
| Operating Income (EBIT) | (70.2M) | (106.7M) | (88.1M) | (64.0M) | (34.7M) |
| Non-Operating | |||||
| Interest Income | 1.3M | 509.0K | 361.0K | (415.0K) | 186.0K |
| Interest Expense | 1.4M | 1.8M | 1.6M | 712.0K | 95.0K |
| Net Interest Income | (74.0K) | 238.0K | (1.3M) | (1.1M) | 46.0K |
| Other Non-Op Income/Expense | 240.0K | 726.0K | 2.1M | 6.5M | (6.6M) |
| Non-Operating Income (excl Interest) | (1.6M) | (2.5M) | (3.7M) | (7.2M) | 6.6M |
| EBT (Pre-Tax Income) | (70.0M) | (105.9M) | (86.0M) | (57.5M) | (41.4M) |
| Income Tax Expense | 4.0K | 3.0K | 2.0K | 2.0K | 1.0K |
| Bottom Line | |||||
| Net Income | (70.0M) | (105.9M) | (86.0M) | (57.5M) | (41.4M) |
| Earnings from Cont. Ops | (70.0M) | (105.9M) | (86.0M) | (57.5M) | (41.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (70.0M) | (105.9M) | (86.0M) | (57.5M) | (41.4M) |
| Per Share | |||||
| Basic EPS | ($4.57) | ($7.09) | ($6.04) | ($4.81) | ($4.96) |
| Diluted EPS | ($4.57) | ($7.09) | ($6.04) | ($4.81) | ($4.96) |
| Revenue Per Share | $0.05 | $0.55 | $2.90 | $3.38 | $3.40 |
| Shares | |||||
| Basic Shares Outstanding | 16.1M | 14.9M | 14.2M | 12.0M | 8.3M |
| Diluted Shares Outstanding | 16.1M | 14.9M | 14.2M | 12.0M | 8.3M |
| Profitability Metrics | |||||
| EBITDA | (65.2M) | (102.4M) | (81.5M) | (55.4M) | (40.2M) |
| D&A | 3.4M | 1.7M | 2.8M | 1.4M | 1.0M |
| EBIT | (68.6M) | (104.1M) | (84.4M) | (56.8M) | (41.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2024